🚀 “Entire software categories are up for grabs.”

Investor Akash Bajwa explains why the next wave of AI‑native startups will rewrite today’s playbooks and how first‑time founders can ride it.

What you’ll learn

• The three‑layer stack (AI chips → models → apps) and the product & data flywheel that lets tiny startups punch above their weight.
• A clear framework for deciding “AI‑native or AI‑assist?” for your startup. Why 2025 feels like a 1994‑style inflection point for builders—and how timing alone can hand newcomers a huge edge.
• Talent‑density tactics: hire “heat‑seeking missiles” and design org charts that scale themselves.
• The coming surge of autonomous agents and micro‑transactions, plus the strange new business models they unlock.
• Five bold 2035 predictions that will reshape product, funding, and daily work.

• 
  

  
  

⏱️ Chapters

0:00 Intro

5:23 What “AI‑native” really means

10:34 Designing lean, taste‑driven teams

20:30 The vertical stack playbook

26:29 Evals as the hidden moat

34:57 Agents 101 and the Model Context Protocol

39:47 Micro‑payments, macro impact

45:22 2035 outlook for founders

56:41 Hiring, culture, and rebellious opinions

1:04:15 Rapid‑fire takeaways

Why subscribe? If you sketch business ideas on napkins, obsess over product‑market fit, or dream of disrupting incumbents with AI, this channel is for you. 🔔 Hit subscribe so Spotify tells you the moment new episodes drop 🔔

Keywords: AI startup, entrepreneur tips, venture capital, SaaS, Earlybird Venture Capital, Akash Bajwa interview, AI‑native products, vertical integration, talent density, autonomous agents, evals, Founders and Builders podcast, build with AI, startup playbook, how to start a tech company, seed fundraising, product strategy, software innovation.#AI #Startups #Entrepreneurship #Software #VentureCapital

💊 90% of drugs fail. Clinical trials take years. And billions are lost every time.

In this episode of Founders & Builders, I sit down with Dr. Olga Kubassova, a mathematician turned biotech investor, and founder of Image Analysis Group — a company using AI-powered imaging biomarkers to reinvent how we measure whether a drug is actually working.

We cover:

🧠 Why clinical trials are broken — and what needs to change

📉 How AI biomarkers let us see disease earlier and treatment faster

⚙️ What makes a billion-dollar drug fail — and how we can spot it sooner

💡 Olga’s journey from math PhD to advising governments and top pharma

🏥 The future of precision medicine and data-driven trials

One of my favorite moments:“If you can see disease earlier and measure treatment faster — that’s the difference between a failed drug and a billion-dollar success.”

This is a conversation about the future of medicine — and how AI is changing everything.

🧬 Most new medicines are billion-dollar bets made in the dark.Charm Therapeutics is changing that — using AI to design drugs that actually work.Laksh Aithani, co-founder and CEO, joins the Founders and Builders podcast to break down how AI is transforming drug discovery — and why Charm raised $50M from Nvidia, General Catalyst, and Khosla Ventures to do it.We talk about:– The wild science behind protein folding– Why most drugs still fail in trials– How Charm slashes R&D timelines using DragonFold– What it really takes to build a biotech company at 27This episode is a window into the future of how medicine gets made.